EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Immunocompatibility of Rad-PC-Rad liposomes in vitro, based on human complement activation and cytokine release

Sofiya Matviykiv, Marzia Buscema, Gabriela Gerganova, Tamás Mészáros, Gergely Tibor Kozma, Ute Mettal, Frederik Neuhaus, Takashi Ishikawa, János Szebeni, Andreas Zumbuehl, Bert Müller

Precision Nanomedicine · 2018

DOI: 10.29016/180419.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision Nanomedicine, 2018. Verfasst von Sofiya Matviykiv und 10 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Seventh Framework Programme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liposomal drug delivery systems can protect pharmaceutical substances and control their release. Systemic administration of liposomes, however, often activate the innate immune system, resulting in hypersensitivity reactions. These pseudo-allergic reactions can be interpreted as activating the complement system. Complement activation destroys and eliminates foreign substances, either directly through opsonization and the formation of the membrane attack complex (MAC), or by activating leukocytes and initiating inflammatory responses via mediators, such as cytokines. In this study, we investigated the in vitro immune toxicity of the recently synthesized Rad-PC-Rad liposomes, analyzing the liposome-induced complement activation. In five human sera, Rad-PC-Rad liposomes did not induce activation, but in one serum high sensitivity via alternative pathway was detected. Such a behavior in adverse phenomena is characteristic for patient-to-patient variation and, thus, the number of donors should be in the order of hundreds rather than tens, hence the present study based on six donors is preliminary. In order to further prove the suitability of mechano-responsive Rad-PC-Rad liposomes for clinical trials, the production of pro-inflammatory cytokines was examined by human white blood cells. The concentrations of the pro-inflammatory cytokines, IL-6, IL-12p70, TNF-α, and IL-1β, induced by Rad-PC-Rad liposomal formulations, incubated with whole blood samples, were smaller or comparable to saline (negative control). Because of this favorable in vitro hemo-compatibility, in vivo investigations using these mechano-responsive liposomes should be designed.

Förderung

  • Seventh Framework Programme

Zitieren

APA

Matviykiv, S., Buscema, M., Gerganova, G., Mészáros, T., Kozma, G. T., Mettal, U., Neuhaus, F., Ishikawa, T., Szebeni, J., Zumbuehl, A., & Müller, B. (2018). Immunocompatibility of Rad-PC-Rad liposomes in vitro, based on human complement activation and cytokine release. Precision Nanomedicine. https://doi.org/10.29016/180419.2

Vancouver

Matviykiv S, Buscema M, Gerganova G, Mészáros T, Kozma GT, Mettal U, et al. Immunocompatibility of Rad-PC-Rad liposomes in vitro, based on human complement activation and cytokine release. Precision Nanomedicine. 2018. doi:10.29016/180419.2

BibTeX
@article{Matviykiv2018,
  author = {Matviykiv, Sofiya and Buscema, Marzia and Gerganova, Gabriela and Mészáros, Tamás and Kozma, Gergely Tibor and Mettal, Ute and Neuhaus, Frederik and Ishikawa, Takashi and Szebeni, János and Zumbuehl, Andreas and Müller, Bert},
  title = {Immunocompatibility of Rad-PC-Rad liposomes in vitro, based on human complement activation and cytokine release},
  journal = {Precision Nanomedicine},
  year = {2018},
  doi = {10.29016/180419.2}
}
Kostenlos starten →